News & Updates

In individuals receiving renin-angiotensin-aldosterone system inhibitor (RAASi) therapy for heart failure with reduced ejection fraction (HFrEF), the novel potassium binder patiromer effectively reduced serum potassium levels, the DIAMOND trial suggests, thus optimizing a guideline-directed RAASi therapy for these patients.

Exercise contributes to an abnormal risk in pulmonary capillary wedge pressure (PCWP), but is not affected by metoprolol, in patients with obstructive hypertrophic cardiomyopathy (HCM), results of a study have shown.

The primary causes of death in patients with acute myocardial infarction complicated by cardiogenic shock (AMICS) are heart failure, neurologic injury, and multiorgan failure (MOF), reports a recent study. Deaths from cardiac causes often occur within 13 hours of the first medical contact.

Prolonged corrected QT interval (QTc), as determined via electrocardiogram (ECG), may indicate an elevated risk of myocardial injury and death in patients hospitalized for COVID-19, according to a prospective study from Israel presented at EHRA 2022.

A history of infertility among women appears to contribute to an increased risk of incident heart failure (HF), reveals a recent study.

Patients with uncontrolled hypertension can benefit from renal sympathetic denervation, which leads to notable reductions in systolic blood pressure (SBP) after 6 months of intervention, reports the proof-of-concept SPYRAL HTN-ON MED trial presented at  ACC.22.